340B Drug Pricing Program
The United States District Court for the District of Columbia today ruled in favor of the AHA, holding that the Department of Health and Human Services must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that…
The United States District Court for the District of Columbia ruled in favor of the AHA, holding that HHS must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that participate in the 340B Drug Pricing Program.
This page contains materials related to AHA’s current and active policy-related litigation.
Judge orders HHS to immediately halt unlawful reimbursement cuts for remainder of 2022 re: 340B.
340B Advocacy Alliance Bulletin for September 27, 2022.
340B Advocacy Alliance Bulletin for September 23, 2022.
Forty-six days from now on Nov. 8 millions of Americans will cast their ballots and exercise their most sacred right – the right to vote.
The U.S. District Court for the District of Columbia should reject HHS' request to devise on its own timeline a remedy for its 2018 and 2019 underpayments to 340B hospitals, with no limitations and no oversight by the court, AHA told the D.C. court yesterday.
In July, the Centers for Medicare & Medicaid Services published its annual outpatient prospective payment system regulation.
The U.S. District Court for the District of Columbia should reject the Department of Health and Human Services’ request to devise on its own timeline a remedy for its 2018 and 2019 underpayments to 340B hospitals, with no limitations and no oversight by the court, AHA told the D.C. court today.